Pfizer has been making headlines because of its work developing a Covid-19 vaccine. On Monday and Tuesday, the company is hoping some of that buzz will rub off on its other research projects, which will be presented in a two-part investor day Monday and Tuesday.

Such meetings are a common way for companies to drum up investor interest. But Mikael Dolsten, Pfizer’s chief scientific officer, said in an interview with STAT that never before in his decadelong tenure running the company’s labs has such a meeting focused so squarely on the company’s research and development efforts, not its financial targets.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy